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Abstract  
The human body has natural systems for vasodilation which are fueled by nitric oxide 
production, but in cases of cardiac disfunction and stress nitric oxide can be inhibited. In this 
study, nitric oxide was studied as a mediator for the blood rush experienced in the warming 
process of induced hypothermia after a major cardiac event. Nitric oxide (NO) was introduced 
through sodium nitrate which was aimed to reduce the speed and turbulence of blood flow. A 
viscometer was used to examine the rate of blood flow, while the temperature was varied to 
simulate the conditions of induced hypothermia. Two temperatures were tested to simulate the 
warming process of induced hypothermia, and three concentrations of sodium nitrate were added 
to the samples. A control was used for comparison and for calculations. The results indicated that 
the 0.11 M NaNO3 expressed constant blood viscosity for both temperatures, the 0.09 M NaNO3 
exhibited some mediation and the 0.10 M showed the least mediation. 
 
Therapeutic Hypothermia 
 Therapeutic cooling has been employed in medicine for a very long time, but with varied 
results. In recent years, several studies have examined induced hypothermia as a treatment after 
cardiac arrest. These studies have concluded that cooling patients slows tissue damage caused 
from cardiac trauma [1,2]. Therapeutic hypothermia, however, contributes to a high mortality 
rate, and many patients who do survive the procedure are left with neurological deficits. A study 
conducted at the Central Lisbon Hospital Center, in Portugal, used induced hypothermia on ICU 
patients and yielded a 61% mortality rate [3]. Hemorrhage and increased blood loss were 
hypothesized as possible causes for this percentage [3,4]. Another study specifically examined 
blood effects from induced hypothermia in perioperative patients and indicated that blood loss 
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was increased by 16% [5]. The increased blood loss was likely the result of the blood rush during 
the hypothermia reversal process. In several cases, it was observed that as the blood was 
warmed, it reacts drastically due to blood shear thinning properties, leading to a blood rush [1,5]. 
This is a biological representation of the inverse relationship between viscosity and temperature, 
which is foreign to the human system. The blood rush can yield brain damage and added stress to 
an already pressured cardiac system. This blood rush has been noted to occur even when the 
warming and cooling processes are done at a very slow rate. In each of the studies referenced, 
the heating and cooling process took approximately 24 hours; however, the effects of the blood 
rush were still present [3,4]. If the rush could be controlled, it might make induced hypothermia 
a much more successful procedure.  
 
Nitric Oxide  
Nitric oxide plays a key physiological role in the cardiovascular, respiratory, digestive, 
immune, and nervous systems [6]. NO acts as a cardiovascular stimulant which relaxes the 
vessels and fuels the pacemaker [7,8, 9]. The NO molecule is produced in the endothelium of the 
blood vessels from the conversion of arginine to citrulline when the cardiac system is healthy [6]. 
Plaque buildup in the vessels can severely impair the ability of nitric oxide to be released [7, 10]. 
Since plaque is a major cause of cardiac disfunction, it is likely that many patients treated with 
induced hypothermia for cardiac arrest would have plaque hindering their ability to produce NO 
[7]. For this reason, an introduction of nitric oxide into the circulatory system during the 
warming process of induced hypothermia may work to normalize the blood flow and contribute 
to restoring the body’s natural homeostasis. As the core temperature is raised, vasodilation and 
sweating are required for heat to dissipate and the vasodilator responsible for this is NO. A study 
examining the blood flow to the skin noted that nitric oxide contributes 30% of the vasodilation 
reflex experienced in the body when heat is dissipated during core cooling [11]. In another study, 
scientists evaluated the amount of NO required by the body to achieve normal blood flow and 
discovered that patients with worse health or heart strain required more NO to propel normal 
circulation [7]. Nitric oxide also has been shown to work in the prevention of plaque in the 
circulatory system, which could aid in the long-term rehabilitation of cardiac arrest patients [7]. 
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Pharmaceutical Use of Nitric Oxide 
Sodium nitrate is an organic salt that is utilized in several medications to introduce nitric 
oxide into the circulatory system. Nitrodilators, which contain sodium nitrate, are currently used 
to relax the blood vessels of hypertensive patients [12]. Sodium nitrate itself has been used in 
patients to prevent cardiac arrest [13]. Sodium nitrate dissociates in vivo to release nitric oxide, 
sodium ions, and diatomic oxygen. Nitric oxide and sodium are diffused out of the bloodstream 
in milliseconds; the oxygen, however, is not [14]. Oxygen remains in the blood much longer than 
the nitric oxide because the NO molecule binds to the allosteric site of the heme group in 
hemoglobin reducing its ability to bind oxygen [15]. Saturating the blood with oxygen over a 
long period of time can be dangerous; therefore, a sodium nitrate treatment would only need to 
be only used in targeted cases for short durations [15,16]. Also, in many cases, patients treated 
with sodium nitrate quickly became accustomed to the treatment, and it no longer yielded an 
effect [12]. Therefore, employing sodium nitrate as a long-term medication would likely be 
fruitless. Studies have not yet explored the benefits of one-time intravenous treatments with 
sodium nitrate in therapeutic hypothermia. The controlled environment required for induced 
hypothermia would aid in controlling the oxygen levels of the patients. This could prevent 
saturation making the introduction of sodium nitrate safer.  
 
Experimental Development  
 The current uses of sodium nitrate in medicine point towards a potential application in 
the blood warming process of induced hypothermia. While there are some negative associations 
connecting high levels of nitrates to cancer, the NO molecule only exists in the blood for 
milliseconds, therefore, the use of sodium nitrate is feasible in specialized procedures [14, 17]. 
Also, the controlled environment required for induced hypothermia would aid in controlling the 
oxygen levels of the patients in order to prevent oxygen saturation. This study hypothesized that 
sodium nitrate would regulate human blood flow when the blood was warmed to mitigate the 
blood rush and bring the blood flow back to homeostasis. The experiment was done to determine 
the interaction between the RBC and nitric oxide and its effect on blood flow as measured by 
viscosity. Blood flow was analyzed in this study using a Zahn cup viscometer at targeted 
temperatures to simulate induced hypothermia. Defibrinated sheep blood was used for the 
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experimentation and samples were tested with no added sodium nitrate as well as three 
concentrations of sodium nitrate. 
 
Methodology 
 Sheep blood was obtained for testing and stored at approximately 1°C with a shelf life of 
28 days. The blood was defibrinated mechanically by the manufacturer, Quad Five, and was 
verified for purity by the USDA [18]. Defibrinated blood is free of anticoagulants which could 
interfere with observation of the experimental induced effects on the blood’s viscosity. 
Defibrinated sheep blood also has been certified to be a viable substitute for human blood in 
diagnostic testing and is used by many companies for experimentation [19].  
 The Zahn Cup size two was used to measure viscosity. The size two Zahn cup had an 
orifice size of 0.108 inches and a capacity of 44 milliliters which was used in the calculation of 
shear rate [20]. Zahn Cup viscometers measure the viscosity of a fluid using the time of efflux 
through the orifice. This brand of viscometer is used to measure the viscosity of paint. Paint is a 
non-Newtonian, shear thinning, fluid just like blood so the Zahn Cup viscometer should give 
applicable results for blood’s viscosity. The design of the Zahn Cup employs gravity to 
determine viscosity which was ideal in reducing added turbulence in the samples [21]. 
 The recommended temperature for use with Zahn cup viscometers is 25°C. However, a 
calibration curve can also be made with a control liquid and careful monitoring of the 
temperature as per the instructions of the manufacturer [20]. A calibration curve was constructed 
for this experiment using defibrinated sheep blood with no salt added. Three trials were taken for 
each degree tested with the average being used to form the curve. The range of temperature was 
set from 25°C to 37°C with trials beginning at the highest temperature. 37°C was set as the upper 
bound of temperature to account for the warming to normal human body temperature. 25°C was 
tested as the cooling temperature and was chosen from the recommendation of use for the Zahn 
Cup viscometer [20]. 25°C is approximately 5 degrees below the average temperature cooled to 
in induced hypothermia, but it was used to provide more accurate readings with the Zahn cup 
viscometer from the manufacturer’s recommendations.  
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 To begin, blood samples were raised from storage temperature to room temperature, 
approximately 22°C. The temperature was then raised slowly to 37°C using a warm water bath 
with temperature control. The warm water bath was raised in increments of 5°C allowing the 
blood to acclimate to the temperature slowly. This prevented the blood from denaturing. When 
the blood reached 37°C the first reading was taken. Readings were taken at each degree 
increment as the blood was cooled to 24°C using an ice bath for cooling.  
 Readings were taken by first submerging the Zahn Cup in the blood and allowing it to 
warm. Once the viscometer had warmed to temperature, the cup was raised to just under flush 
with the top of the blood. The cup was then raised vertically six inches and placed on a hook set 
over the center of the collection beaker. A stopwatch was started as the cup broke the surface of 
the blood and was stopped when the first break in the flow of the blood was observed [20]. 
Between each reading the Zahn cup was rinsed to prevent cohesion which could alter the flow 
time. The Zahn cup was cleaned completely in between each concentration to avoid 
contamination.  
 Sodium nitrate solutions were then made by diluting the salt in water. The amount of 
sodium nitrate to dilute was calculated using the concentration of salt administered in a typical 
IV bag of sodium chloride given for dehydration [22]. The calculated concentration was 0.10 M 
NaNO3. 0.09 M and 0.11 M NaNO3 were also tested to account for the difference in molecular 
weight of sodium nitrate and sodium chloride as well as to account for different rates of 
dissociation for each salt in the blood. Ten trials were run at each sodium nitrate concentration 
for 25°C and 37°C. The average of these ten trials, excluding major outliers, were considered in 
the final analysis of viscosity. Outliers were categorized as any values which were ± 0.20 away 
from the closest flow time.  
Blood samples were also examined using the highest objective on a compound  
microscope to determine if the sodium nitrate solutions were causing any abnormalities in the  
structure of the blood. Samples of the defibrinated sheep blood as well as human blood samples  
were examined to determine the safety of the sodium nitrate. The human blood samples were  
drawn by a certified phlebotomist, Jennifer Love, from the experimenter, Brianna Munnich, with  
consent. The purpose of these qualitative observations was both to make sure that the  
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defibrinated sheep blood had not denatured and to determine if the sodium nitrate would affect  
the structure of the blood.  
 All blood and instruments which met blood were handled using medical grade gloves and 
goggles. These safety procedures also ensured that the blood was not contaminated  
during testing.  Blood was disposed of properly using biohazard procedures. All beakers and  
utensils which touched the blood were also washed using biohazard procedures during each  
change of concentration and temperature in the experiment.  
 
Results 
 
TABLE 1. CONTROL TEMPERATURE CURVE 
DATA FOR BLOOD WITH NO SODIUM NITRATE 
  TEMP.  
(°C) 
Flow Time 
(sec) 
DV  
(PA∙s) 
Shear Rate 
(1/s) 
25 15.18 4.4 x 10-3 1.22 
26 15.10 4.1 x 10-3 1.23 
27 14.96 3.6 x 10-3 1.24 
28 14.93 3.5 x 10-3 1.24 
29 14.94 3.5 x 10-3 1.24 
30 14.89 3.3 x 10-3 1.26 
31 14.80 3.0 x 10-3 1.26 
32 14.58 2.1 x 10-3 1.27 
33 14.64 2.4 x 10-3 1.27 
34 14.64 2.4 x 10-3 1.27 
35 14.80 2.9 x 10-3 1.25 
36 14.77 2.9 x 10-3 1.26 
37 14.60 2.2 x 10-3 1.27 
shear rate. Blood is a shear-thinning fluid so it should be modeled with apparent viscosity [21]. 
This is because blood aggregates due to its colloidal structure. For each concentration and 
temperature tested the apparent viscosity was tabulated and evaluated in Pascal seconds. The 
 
 The results in Table 1  
show the gathered data for the  
control curve. From 25°C to 32°C 
a decreased dynamic viscosity  
occurs as the temperature  
increases. From 32°C to 37°C  
a blood rush appears with an  
increase in dynamic viscosity  
followed by a quick reduction to  
the minimum dynamic viscosity.  
 
Apparent Viscosity  
The apparent viscosity is a 
comparison of the dynamic 
viscosity to the rate at which the  
fluid shears. Apparent viscosity is 
used to model non-Newtonian 
fluids which do not have a constant  
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ranges seen in the apparent viscosity across the trials indicate the influence of temperature on the 
shear stress causing turbulence in the sample.  
 
Calculation of Dynamic Viscosity  
 Kinematic viscosity was calculated using the formula provided with the Zahn cup 
viscometer: KV=3.5 (t-14) [20]. To convert from kinematic viscosity to dynamic viscosity, the 
kinematic viscosity was multiplied by the density of blood, 1.06 [23]. Lastly, the dynamic 
viscosity was converted to Pa∙s.  
 
Sample Calculation of Dynamic Viscosity  
Calculation was done using the flow time of 15.18 seconds from the 25°C control trial.  
𝐾𝑉 = 3.5 (𝑡 − 14) 
𝐾𝑉 = 3.5 (15.18 − 14)                     𝐾𝑉 = 4.13 𝑚Pa ∙ s 
𝐷𝑉 =  𝜌 × 𝐾𝑉                                   𝐷𝑉 = 1.06(4.13)                             𝐷𝑉 = 4.3778 𝑚𝑃𝑎 ∙  𝑠 
1 Pa ∙ s = 1,000 m Pa ∙ s                     𝐷𝑉 =  
4.3778
1,000
                                   𝐷𝑉 = 4.4 𝑥 10−3 𝑃𝑎 ∙  𝑠 
 
Calculation of Control Shear Rate for Expressing Apparent Viscosity
The shear rate was calculated by dividing the velocity in m/s by the height the blood fell 
from the top of the Zahn cup to the blood’s exit at the orifice. These measurements were 
obtained from the instructions provided with the Zahn cup size two viscometer [20]. 
 
Sample Calculation of Shear Rate  
Calculation was done using the flow time of 15.18 seconds from the 25°C control trial.  
𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 𝑜𝑓 𝐵𝑙𝑜𝑜𝑑 𝐹𝑙𝑜𝑤 =  
ℎ𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑏𝑙𝑜𝑜𝑑 𝑓𝑎𝑙𝑙
𝑓𝑙𝑜𝑤 𝑡𝑖𝑚𝑒
           𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =
0.0508
15.18
 = 3.3 x 10-3    
𝑆ℎ𝑒𝑎𝑟 𝑟𝑎𝑡𝑒 =
𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦
ℎ𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑧𝑎ℎ𝑛 𝑐𝑢𝑝
    𝑆ℎ𝑒𝑎𝑟 𝑟𝑎𝑡𝑒 =
3.3 𝑥 10−3
0.00274
     𝑆ℎ𝑒𝑎𝑟 𝑟𝑎𝑡𝑒 = 1.22 1/𝑠 
 
Considerations for Result Interpretation  
 The data taken for the 0.09 M NaNO3, 0.10 M NaNO3, and 0.11 M NaNO3 are  
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represented as averages taken from the ten trials taken at 25°C and 37°C. The averages were 
calculated while excluding major outliers. Outliers in this experiment are designated as any  
values which were within a ± 0.20 separation of flow time data. Outliers were removed to 
account for the human error caused from lifting the Zahn cup improperly or timing errors.  
Human error was also minimized by repeating the runs ten times until values were repeated or  
had very little deviation. Frequently values will be compared to normal human blood viscosity  
which is between 3.0 x 10-3 and 4.0 x 10-3 Pascals per second [24]. 
In Figure 1, the results of the control data by degree are plotted versus the calculated  
dynamic viscosity. The trendline obtained from the control curve was used to determine the 
deviation of the sodium nitrate 
trials. This plot was also 
constructed in order to 
determine if the experimental 
model exhibited the expected 
trend without a changed 
variable.  
The data in Figure 1 
exhibited an inverse relationship 
between the flow rate of the 
blood. A blood rush was also observed in the control trials from 32°C to 37°C as described in the 
literature. Between 31°C and 32
°C a dramatic decrease is 
observed in the dynamic 
viscosity which brings the 
dynamic viscosity to nearly 
0.001 below the range of normal 
human blood viscosity. From 32
°C to 36°C an increase in 
dynamic viscosity is observed, but it does not return to the normal range of human blood 
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viscosity. Another, dip is seen from 36°C to 37°C. The dynamic viscosity at 37°C lies below the 
range for normal human blood viscosity and is likely a result of two factors. These are the lack of 
vessel induced friction in the experimental model as well as the blood rush phenomenon 
increasing shear stress and eddies in the blood samples. Figure 2 expresses the apparent viscosity 
through the comparison of the dynamic viscosity and the shear rate of the blood flow for the 
control temperatures. The trendline on this plot was used in further comparisons of the trials 
employing sodium nitrate to evaluate deviations.  
In Figure 3, each concentration of sodium nitrate is compared by apparent viscosity for  
the 25°C trials. The minima, maxima, and averages for each concentration are depicted along 
with a trendline to express the turbulence of the blood sample. The 0.09 M NaNO3 had the 
highest viscosity range due to a larger maximum, minimum, and average value. The trendline 
does not include the average 
marker indicating that this 
concentration of sodium nitrate 
experienced turbulence. The 
data points for the 0.09 M 
concentration do not lie within 
the normal range for human 
blood viscosity. The trials 
employing 0.10 M NaNO3 and 
0.11 M NaNO3 had similar 
ranges and averages with little 
deviation and each trendline contains all three data points. The 0.10 M slope is steeper than the 
0.11 M NaNO3 with a more consistent slope to the 0.09 M concentration. The averages for the 
0.10 M and 0.11 M concentrations fell within the range for normal human blood viscosity. The 
ranges for the 0.10 M and 0.11 M trials were much narrower than the 0.09 M trial with the  
0.11 M being the narrowest of the concentrations of sodium nitrate. The ranges for each of the 
concentrations exceed the limits for normal human blood viscosity on the upper and lower bound 
indicating that turbulence is still experienced in each sample. 
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In Table 2, the trends from Figure 3 are clearly defined. It is clear from the Figure 3 as 
well as Table 2 that the 0.09 M concentration of sodium nitrate was the only concentration to lie  
outside of the normal range for human blood viscosity at 25°C at both temperatures as well as 
the average. Table 2 illustrates the inverse relationship between the shear rate and the dynamic 
viscosity as well as clarifies the averages seen in the 0.10 M and 0.11 M concentration which are 
tightly packed in Figure 3. The average dynamic viscosity for the 0.10 M concentration of 
sodium nitrate is the lowest of the three trials at 25°C, but it still very close to the value 
calculated for the 0.11 M concentration. The 0.10 M and 0.11 M concentrations are very close in 
values while the 0.09 M concentration is separated from the rest of the data.   
In Figure 4, the apparent viscosity is compared for each concentration of sodium nitrate  
at 37°C representing the warming phase of induced hypothermia. The minima, maxima, and 
averages for each concentration are depicted along with a trendline to express the flow of the 
blood sample. The 0.09 M 
concentration had a very 
narrow range with all but the 
maximum value within the 
range for normal human blood 
viscosity. The 0.10 M 
concentration had more 
deviation between its maximum 
and minimum than the 0.09 M 
concentration and only its 
maximum was within the 
Table 2. Apparent Viscosity of Various Concentrations of NaNO3 at 25°C 
 Avg. Flow Time (s) Avg. DV (Pa∙s) Shear rate (1/s) 
           0.09 M NaNO3 15.12 4.2 x 10
-3 1.22 
0.10 M NaNO3 14.87 3.3 x 10
-3 1.25 
0.11 M NaNO3 14.93 3.5 x 10
-3 1.24 
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normal range for human blood viscosity. The 0.11 M concentration had the largest deviation in 
its range, but its average was within the area for normal human blood viscosity. The trendlines 
for the 0.09 M and 0.11 M concentrations are very similar. The 0.10 M trendline is lower in 
value than the other two concentrations tested. The maximum and average portions of the ranges 
were within normal human blood viscosity for the 0.09 M and 0.11 M concentrations. The 
minimums for the 0.10 M and 0.11 M fell below the normal range for human blood viscosity 
likely due to similar differences in the experimental model as discussed for the control data. 
In Table 3, the average values at 37°C are expressed to clarify between close values in 
Figure 4. Table 3 shows that the 0.09 M and 0.11 M concentration were closer in value than the 
0.10 M concentration. The 0.10 M concentration had the lowest dynamic viscosity and was also 
the only concentration that was below the normal value for human blood viscosity.  
 
In Figure 5, the average dynamic viscosities were plotted to show the change between  
 Table 3. Apparent Viscosity of Various Concentrations of NaNO3 at 37°C  
 Avg. Flow Time (s) Avg. DV (Pa∙s) Shear rate (1/s) 
0.09 M NaNO3 15.03 3.8 x 10
-3 1.23 
           0.10 M NaNO3 14.76 2.8 x 10
-3 1.26 
0.11 M NaNO3 14.93 3.5 x 10
-3 1.24 
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25°C and 37°C for each of the concentrations of sodium nitrate as well as the control. The slopes 
of each sample indicate whether the viscosity change was mediated during the warming of the 
blood. The control sample had the largest variance in dynamic viscosity with a range from  
4.4 x 10-4 to 2.2 x 10-4 and a net change of 2.2 x 10-3. The 0.10 M NaNO3 had the next largest 
change in dynamic viscosity over the two temperatures with a change of 6.0 x 10-4. This was the 
largest variance of the sodium nitrate trials and it ended with a dynamic viscosity that is not 
within the range of normal human blood viscosity. The 0.09 M and 0.11 M concentrations have 
relatively flat slopes with very low change over the two temperatures. The 0.09 M concentration 
had a net change of 1.0 x 10-4 and the 0.11 M concentration showed no change over the two  
temperatures. The 0.09 M and 0.11 M concentrations of sodium nitrate both lie within the range  
for normal human blood viscosity at 25°C and 37°C.  
In Table 4, the results of the graph are tabulated into calculations to more precisely  
differentiate between the different trials over the course of the two temperatures tested.  
Table 4. Deviation of Dynamic Viscosity (DV) from the Control as the Samples were Warmed 
 Δ DV 
(Pa∙s) 
Deviation of 
Slope   
Deviation of DV 
at 25°C 
Deviation of DV 
at 37°C 
0.09 M NaNO3 1.0 x 10
-4 1.92 x 10-4 5.0 x 10-4 1.6 x 10-3 
 0.10 M NaNO3 6.0 x 10
-4 1.50 x 10-4 1.0 x 10-3 2.8 x 10-3 
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The 0.09 M and 0.11 M concentrations had a larger deviation in slope from the control with the  
values 1.92 x 10-4 and 1.99 x 10-4 respectively. A smaller deviation was observed in the 0.10 M  
concentration of 1.50 x 10-4. At 25° C the deviation for the 0.10 M concentration is much larger 
than for the 0.09 M and 0.11 M concentration. The 0.09 M and 0.10 M concentrations exhibit a 
smaller change at the 25°C temperature as shown by their higher values when cooled. 
Conversely the 0.10 M concentration experienced the lowest deviation at 37°C due to its steeper 
slope in comparison to the other concentrations of sodium nitrate tested. The 0.09 M 
concentration of sodium nitrate was the furthest deviated from control with a value of 1.6 x 10-3 
followed closely by the 0.11 M concentration at a value of 1.3 x 10-3. These samples experienced 
more deviation because they did not experience the dip in dynamic viscosity due to the increase 
in temperature in the blood rush region. 
 
Analysis 
 The control curve displayed in Figure 1 exhibited the expected pattern of decreased  
temperature and increased viscosity. At 32°C variation seen in the viscosity illustrates  
the blood rush phenomenon which was the focus of observation in the experiment. The  
viscosities at 25°C and 37°C are out of the range of normal human blood viscosity so the results  
of the control are not optimal for comparison to the sodium nitrate trials therefore slopes were 
examined more closely for comparison. The steep decrease in dynamic viscosity may have been 
caused by the lack of friction from the Zahn cup in comparison to a blood vessel.  
The 0.09 M NaNO3 showed some signs of mediation with a very small decrease in  
dynamic viscosity between the 25°C and 37°C measurements. At both tested temperatures  
the dynamic viscosity for the 0.09 M NaNO3 stayed within the range of normal human blood  
viscosity. In comparison to the other trials the 0.09 M concentration of sodium nitrate was the  
second most effective at maintaining the constant viscosity during the warming of the blood.  
 The 0.10 M NaNO3 showed varied results with a much steeper decrease in dynamic  
0.11 M NaNO3 0 1.99 x 10
-4 9.0 x 10-4 1.3 x 10-3 
Control 2.2 x 10-3 n/a n/a n/a 
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viscosity when the temperature was raised than the other two concentrations of sodium nitrate  
tested. The dynamic viscosity at 25°C was within the range of normal human blood viscosity, but  
over the warming process the dynamic viscosity was lowered to below the normal range for  
human blood viscosity. The dynamic viscosity for the 0.10 M NaNO3 was expected to lie  
between the 0.09 M and 0.11 M concentrations of sodium nitrate when measured at 25°C, but it 
did not indicating a possible error in the experimental model.  
 The 0.11 M NaNO3 expressed the greatest amount of mediation with an unchanging  
dynamic viscosity over the two temperatures tested. Both dynamic viscosity measurements  
taken lie within the range for normal human blood viscosity. In comparison to the other  
measurements taken for each concentration it was hypothesized that more nitric oxide may be  
released for the higher concentrations of sodium nitrate which lead to greater mediation. The  
0.10 M NaNO3 did not follow the pattern of this hypothesis, but it possibly due to error in the 
0.10 M NaNO3 trial. 
Several errors occurred over the course of this experiment which affected the results  
obtained. The friction caused by the metal of the Zahn cup is much different than the friction  
caused by a blood vessel. This limits the full potential of the blood reactivity to temperature to be  
realized so the inhibition may not be seen in a living organism.  The Zahn cup is also not reactive  
to vasodilation which means the nitric oxide likely would have a very different result in vivo due  
to the high permeability of nitric oxide and its role as a neurotransmitter for vasodilation. Also,  
the procedure in this experiment employed gravity to promote blood flow whereas normal  
circulation is propelled even against gravity. The experimental model also does not account for  
the presence of plaque in the circulatory system inhibiting blood flow which is a more accurate  
depiction of flow for a patient undergoing induced hypothermia. Finally, since the experiment  
was conducted ex vivo it cannot be known with certainty that this method is safe to conduct or if 
there are any adverse effects to the treatment.  
Human error is also present in this experiment due to the extensive amount of  
multitasking and timing in order to conduct the experiment. When analyzing the data, error was  
assumed to have made the apparent viscosity values lower than they would be under normal  
circulatory conditions. This is prominent in the control curve which has values which lie outside 
of the normal range of human blood viscosity.  
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The use of sheep blood itself may also account for several errors. One inconsistency may 
be faster flow times due to the tightly packed structure of the sheep blood in comparison to 
human blood. This structure may also affect the for the amount of the nitric oxide bound to heme 
groups. This is because when examined the sheep blood appeared to have more RBCs per unit of 
area than the human blood so nitric oxide could bind in more locations effectively slowing the 
blood more than in a human sample. Sheep blood may also have a higher affinity for nitric oxide 
than human blood which could skew the results of the experiment.  
Degradation of the blood samples overtime also effected the extent of experimentation  
and possibly the results of the 0.10 M NaNO3 sample. The shelf life of the blood when stored and  
properly cared for is approximately 28 days however, it lasts longer when it is frozen and treated  
with anticoagulants. The blood employed in this experiment was not frozen and was defibrinated  
for testing purposes due to this the RBCs likely degraded quicker than expected. The 0.10 M  
concentration was the final concentration tested due to the several changes in the procedure  
which called for retesting. It is possible that the RBCs had denatured causing it to flow faster 
than the other concentrations examined skewing the results. This trial also could have been 
denatured during heating of the blood to 37°C too quickly. This risk of degradation also stopped 
testing lowering the extent of accuracy and limiting improvements to the experimental model.  
 
Conclusion 
 In this experiment sodium nitrate was examined as a method to introduce nitric oxide into  
the circulatory system of patients who are undergoing induced hypothermia. The viscosity of the  
blood was measured in order to determine how the sodium nitrate would affect the flow rate. In  
order to lower the mortality rate associated with induced hypothermia, the flow rate of the blood  
as it is warmed would need to be slowed to avoid the effects of the blood rush. To examine the  
sodium nitrate’s ability to slow the flow rate of blood two temperatures were tested, 25°C and 
37°C. 25°C was used to simulate the temperature patients are lowered to for induced 
hypothermia and 37°C models the temperature patients are raised to after treatment. Each  
concentration was compared at each temperature to determine if the blood rush was impeded.  
 Upon analyzing the data, the 0.11 M NaNO3 was the most effective at maintaining the  
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blood’s viscosity after raising the blood’s temperature. This concentration had concurrent values  
for both temperatures.  The 0.09 M concentration of NaNO3 also expressed some mediation with 
a low amount of variation in dynamic viscosity as the blood was warmed from 25°C to 37°C. 
The 0.10 M NaNO3 did not show mediation as effectively as the other two samples tested. There 
was a large comparative disparity between the two temperatures tested which more closely 
resembled the control. Neither the initial nor final temperature for the 0.10 M concentration were 
found between the 0.09 M and 0.11 M concentration of sodium nitrate as they were expected to 
be. These odd results were likely caused from the degradation of the blood as discussed 
previously as an experimental error.  
 Due to these results no solidified conclusions can be made as to whether sodium nitrate  
mediated the effects of the blood rush during the warming process of induced hypothermia. The  
skew seen in the 0.10 M NaNO3 trial’s data produced doubt as to whether the mediation seen in  
the other nitrate trials were valid. I do believe that a correlation is present which relates nitric  
oxide to a decreased blood flow due to an interaction in the blood between the hemoglobin and  
bound nitric oxide. The correlation is likely because none of the trials lowered to the level of the 
control at 37°C even the 0.10 M NaNO3. Error induced from the rerun of the 0.10 M NaNO3 
close to the expiration date of the blood possibly lead to the degradation of the RBC’s reducing 
the ability of the hemoglobin to interact with the nitric oxide which could account for the 
decreased viscosities in this trial.  
 In order to verify that there is a correlation between decreased viscosity and intake of  
nitric oxide more trials need to be taken and the experimental design should also be improved to  
obtain more accurate results. One of the large unknowns in this experimental design is that the  
amount of nitric oxide introduced into the blood is not certain because it can only be assumed  
that higher concentrations of sodium nitrate release more nitric oxide into the blood. In future  
experiments the levels of ornithine, citrulline, and arginine should be monitored in the blood  
before and after the addition of nitric oxide to determine the relative release of nitric oxide in the  
blood. More improvements can be made to the experiment by testing each degree in the warming  
process from 32°C and 37°C for each concentration to create a better curve for correlation. The 
correlation between nitric oxide introduction and dynamic viscosity would be better verified 
using only one concentration of nitric oxide to narrow the focus of the experiment. Finally, a 
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more precise viscometer should be used in future experiments that better models blood flow as 
well as reduces the human error associated with the fast flow times. Much more information 
could be gathered if the experiment was carried into a more realistic ex vivo model.  
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